vs

Side-by-side financial comparison of Cytosorbents Corp (CTSO) and Linde plc (LIN). Click either name above to swap in a different company.

Cytosorbents Corp is the larger business by last-quarter revenue ($9.2M vs $8.8M, roughly 1.1× Linde plc). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs 0.9%). Linde plc produced more free cash flow last quarter ($898.0K vs $-4.9M). Over the past eight quarters, Cytosorbents Corp's revenue compounded faster (1.3% CAGR vs -96.7%).

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

CTSO vs LIN — Head-to-Head

Bigger by revenue
CTSO
CTSO
1.1× larger
CTSO
$9.2M
$8.8M
LIN
Growing faster (revenue YoY)
LIN
LIN
+7.3% gap
LIN
8.2%
0.9%
CTSO
More free cash flow
LIN
LIN
$5.8M more FCF
LIN
$898.0K
$-4.9M
CTSO
Faster 2-yr revenue CAGR
CTSO
CTSO
Annualised
CTSO
1.3%
-96.7%
LIN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CTSO
CTSO
LIN
LIN
Revenue
$9.2M
$8.8M
Net Profit
$-5.5M
Gross Margin
73.7%
48.5%
Operating Margin
-47.5%
27.8%
Net Margin
-59.5%
Revenue YoY
0.9%
8.2%
Net Profit YoY
27.4%
EPS (diluted)
$-0.09
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTSO
CTSO
LIN
LIN
Q1 26
$8.8M
Q4 25
$9.2M
$8.8B
Q3 25
$9.5M
$8.6B
Q2 25
$9.6M
$8.5B
Q1 25
$8.7M
$8.1B
Q4 24
$9.2M
$8.3B
Q3 24
$8.6M
$8.4B
Q2 24
$8.8M
$8.3B
Net Profit
CTSO
CTSO
LIN
LIN
Q1 26
Q4 25
$-5.5M
$1.5B
Q3 25
$-3.2M
$1.9B
Q2 25
$1.9M
$1.8B
Q1 25
$-1.5M
$1.7B
Q4 24
$-7.6M
$1.7B
Q3 24
$-2.8M
$1.6B
Q2 24
$-4.3M
$1.7B
Gross Margin
CTSO
CTSO
LIN
LIN
Q1 26
48.5%
Q4 25
73.7%
Q3 25
70.3%
Q2 25
70.9%
Q1 25
71.1%
Q4 24
68.4%
Q3 24
61.0%
Q2 24
73.5%
Operating Margin
CTSO
CTSO
LIN
LIN
Q1 26
27.8%
Q4 25
-47.5%
23.0%
Q3 25
-30.2%
27.5%
Q2 25
-37.6%
27.7%
Q1 25
-44.5%
26.9%
Q4 24
-37.1%
27.4%
Q3 24
-56.1%
25.0%
Q2 24
-40.4%
26.4%
Net Margin
CTSO
CTSO
LIN
LIN
Q1 26
Q4 25
-59.5%
17.5%
Q3 25
-33.4%
22.4%
Q2 25
20.2%
20.8%
Q1 25
-16.9%
20.6%
Q4 24
-82.7%
20.8%
Q3 24
-32.1%
18.5%
Q2 24
-48.6%
20.1%
EPS (diluted)
CTSO
CTSO
LIN
LIN
Q1 26
$3.98
Q4 25
$-0.09
$3.28
Q3 25
$-0.05
$4.09
Q2 25
$0.03
$3.73
Q1 25
$-0.02
$3.51
Q4 24
$-0.14
$3.61
Q3 24
$-0.05
$3.22
Q2 24
$-0.08
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTSO
CTSO
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$6.2M
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$5.9M
$40.1M
Total Assets
$44.2M
$86.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTSO
CTSO
LIN
LIN
Q1 26
$4.0M
Q4 25
$6.2M
$5.1B
Q3 25
$7.5M
$4.5B
Q2 25
$10.2M
$4.8B
Q1 25
$11.6M
$5.3B
Q4 24
$3.3M
$4.8B
Q3 24
$5.7M
$5.2B
Q2 24
$8.5M
$4.6B
Total Debt
CTSO
CTSO
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$13.8M
$17.5B
Q2 24
$13.7M
$16.9B
Stockholders' Equity
CTSO
CTSO
LIN
LIN
Q1 26
$40.1M
Q4 25
$5.9M
$38.2B
Q3 25
$9.0M
$38.6B
Q2 25
$11.6M
$38.5B
Q1 25
$14.5M
$38.0B
Q4 24
$11.1M
$38.1B
Q3 24
$13.4M
$39.2B
Q2 24
$17.4M
$38.2B
Total Assets
CTSO
CTSO
LIN
LIN
Q1 26
$86.3M
Q4 25
$44.2M
$86.8B
Q3 25
$45.8M
$86.0B
Q2 25
$48.0M
$86.1B
Q1 25
$50.8M
$82.7B
Q4 24
$47.4M
$80.1B
Q3 24
$47.8M
$82.5B
Q2 24
$53.4M
$80.2B
Debt / Equity
CTSO
CTSO
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
1.03×
0.45×
Q2 24
0.78×
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTSO
CTSO
LIN
LIN
Operating Cash FlowLast quarter
$-4.8M
Free Cash FlowOCF − Capex
$-4.9M
$898.0K
FCF MarginFCF / Revenue
-53.4%
10.2%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.5M
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTSO
CTSO
LIN
LIN
Q1 26
Q4 25
$-4.8M
$3.0B
Q3 25
$-2.6M
$2.9B
Q2 25
$-1.5M
$2.2B
Q1 25
$-3.5M
$2.2B
Q4 24
$-2.3M
$2.8B
Q3 24
$-2.5M
$2.7B
Q2 24
$-4.8M
$1.9B
Free Cash Flow
CTSO
CTSO
LIN
LIN
Q1 26
$898.0K
Q4 25
$-4.9M
$1.6B
Q3 25
$-2.6M
$1.7B
Q2 25
$-1.5M
$954.0M
Q1 25
$-3.5M
$891.0M
Q4 24
$-2.4M
$1.6B
Q3 24
$-2.6M
$1.7B
Q2 24
$-4.8M
$796.0M
FCF Margin
CTSO
CTSO
LIN
LIN
Q1 26
10.2%
Q4 25
-53.4%
17.9%
Q3 25
-27.3%
19.4%
Q2 25
-16.1%
11.2%
Q1 25
-39.7%
11.0%
Q4 24
-26.3%
18.8%
Q3 24
-30.4%
19.9%
Q2 24
-54.4%
9.6%
Capex Intensity
CTSO
CTSO
LIN
LIN
Q1 26
Q4 25
1.2%
16.6%
Q3 25
0.2%
14.8%
Q2 25
0.4%
14.8%
Q1 25
0.0%
15.7%
Q4 24
0.8%
15.1%
Q3 24
1.8%
12.8%
Q2 24
0.2%
13.7%
Cash Conversion
CTSO
CTSO
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
-0.78×
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTSO
CTSO

Direct$5.1M55%
Distributors And Strategic Partners$4.2M45%

LIN
LIN

Segment breakdown not available.

Related Comparisons